615695
|
HSPB1
|
Normal
|
expression
|
Response to gemcitabine
|
|
ABL1
|
High
|
GoF
|
Response to ABL TK inhibitors (imatinib, desatininb, ponatinib, regorafenib …)
|
|
AKT1
|
High
|
GoF
|
Response to PI3K, AKT, MTOR inhibitors; resistance to BRAF inhibitors
|
|
ERBB2
|
High
|
GoF
|
Response to ERBB2, EGFR, MTOR, AKT inhibitors
|
|
MAPK3
|
High
|
GoF
|
Resistance to EGFR inhibition
|
519217
|
HSPB1
|
Normal
|
expression
|
Response to gemcitabine
|
|
CTNNB1
|
High
|
GoF
|
Response to everolimus + letrozole; resistance to Tankyrase inhibitors
|
|
EGFR
|
High
|
GoF
|
Response to EGFR, ERBB2, HSP90 and MEK inhibitors
|
|
ERBB2
|
High
|
GoF
|
Response to ERBB2, EGFR, MTOR, AKT inhibitors
|
|
JUN
|
High
|
overexpr
|
Response to irbesartan (angiotensin II antagonist)
|
|
MCL1
|
High
|
GoF
|
Resistance to anti-tubulin agents
|
|
PTPN11
|
High
|
GoF
|
Response to MEK inhibitors
|
615233
|
FOS
|
High
|
overexpr
|
Response to irbesartan (angiotensin II antagonist)
|
|
PTPN11
|
High
|
GoF
|
Response to MEK inhibitors
|
150990
|
HSPB1
|
Normal
|
expression
|
Response to gemcitabine
|
|
ESR1
|
High
|
GoF
|
Response to novel ER degraders, fulvestrant, tamoxifen
|